Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

NCT04540042 is registered in ClinicalTrials.gov with Tetherex Pharmaceuticals Corporation as lead sponsor.

NCT NCT04540042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04540042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
Lead sponsor
Tetherex Pharmaceuticals Corporation
Phase
Phase 2
Overall status
Completed
Start date
August 18, 2020
Completion date
January 13, 2022
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic obstructive pulmonary disease